Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
OncoCyte Corp (OCX)
NASDAQ:OCX
OncoCyte (OCX) Stock Price & Analysis
404 Followers
OCX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.08 - $4.64
Previous Close$3.24
Volume7.93K
Average Volume (3M)40.11K
Market Cap
$42.37M
Enterprise Value$28.12M
Total Cash (Recent Filing)$14.24M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 07, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.27
Shares Outstanding13,364,637
10 Day Avg. Volume33,497
30 Day Avg. Volume40,111
Standard Deviation0.25
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-1.98
Price to Sales (P/S)39.48
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-11.91
Enterprise Value/Gross Profit-1.56K
Enterprise Value/Ebitda11.94
Forecast
1Y Price Target
$4.25Price Target Upside32.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
OncoCyte News
PremiumCompany Announcements
OncoCyte Announces Andrea James as New CFO and Principal Officer
PremiumCompany Announcements
OncoCyte Executive Team Receives Significant Salary Increases
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOCX beat consensus revenue which reflects its ability to surpass market expectations.
Product LaunchOCX expects to launch GraftAssure RUO and start signing on transplant centers ahead of its launch of VitaGraft Kidney kitted test.
Strategic PartnershipsThe partnership with Bio-Rad Laboratories signifies a strategic move to commercialize OCX's GraftAssure tests.
Bears Say
Pharmaceutical ServicesSale of a majority stake in DetermaRx and lower Pharmaceutical Services revenue, which was down 41% Y/Y.
RevenueThe company's revenue was down 72% Y/Y after selling a majority stake in DetermaRx.
RevenueOCX missed consensus revenue in 1Q24 and its revenue was down 76% Y/Y.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCX FAQ
What was OncoCyte Corp’s price range in the past 12 months?
OncoCyte Corp lowest stock price was $2.08 and its highest was $4.64 in the past 12 months.
What is OncoCyte Corp’s market cap?
Currently, no data Available
When is OncoCyte Corp’s upcoming earnings report date?
OncoCyte Corp’s upcoming earnings report date is Aug 07, 2024 which is in 13 days.
How were OncoCyte Corp’s earnings last quarter?
Currently, no data Available
Is OncoCyte Corp overvalued?
According to Wall Street analysts OncoCyte Corp’s price is currently Undervalued.
Does OncoCyte Corp pay dividends?
OncoCyte Corp does not currently pay dividends.
What is OncoCyte Corp’s EPS estimate?
OncoCyte Corp’s EPS estimate is -$0.56.
How many shares outstanding does OncoCyte Corp have?
OncoCyte Corp has 13,364,637 shares outstanding.
What happened to OncoCyte Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OncoCyte Corp?
Among the largest hedge funds holding OncoCyte Corp’s share is Defender Capital, LLC.. It holds OncoCyte Corp’s shares valued at N/A.
---
OncoCyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (32.40% Upside)
$4.25 (32.40% Upside)
Hedge Fund Trend
Decreased
By 71.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.90%
12-Months-Change
Fundamentals
Return on Equity
-132.29%
Trailing 12-Months
Asset Growth
-14.28%
Trailing 12-Months
Company Description
OncoCyte Corp
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.
---
OCX Earnings Call
Q1 2024
0:00 / 0:00
---
OCX Stock 12 Month Forecast
Average Price Target
$4.25
▲(32.40% Upside)
Technical Analysis
Best Analysts Covering OCX
1 Year
1 Year Success Rate
3/19 ratings generated profit
1 Year Average Return
-59.86%
reiterated a buy rating 2 months ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -59.86% per trade.
---